Vice President, Early Development, Sage Therapeutics
Helen is currently Vice President, Early Development at Sage Therapeutics, a company whose vision it is to fearlessly lead the way to create a world with better brain health. Helen led the development program at Sage that culminated in FDA approval of Zulresso for the treatment of Post-partum Depression. Helen’s current responsibilities include oversight of the transition of programs from Research into Development and through Early Development. Helen’s career has included working for large and small biotechnology and pharma companies, as well as work in consulting and medical devices.
